Cargando…
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
CD73, a cell surface 5′nucleotidase that generates adenosine, has emerged as an attractive therapeutic target for reprogramming cancer cells and the tumor microenvironment to dampen antitumor immune cell evasion. Decades of studies have paved the way for these findings, starting with the discovery o...
Autores principales: | Harvey, Jerry B., Phan, Luan H., Villarreal, Oscar E., Bowser, Jessica L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174602/ https://www.ncbi.nlm.nih.gov/pubmed/32351498 http://dx.doi.org/10.3389/fimmu.2020.00508 |
Ejemplares similares
-
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023) -
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
por: de Leve, Simone, et al.
Publicado: (2019) -
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
por: Wang, Ding-Kang, et al.
Publicado: (2021) -
The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment
por: Sun, Pengcheng, et al.
Publicado: (2022) -
Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer
por: Kowash, Ryan R., et al.
Publicado: (2023)